Navigation Links
Cancer Immunotherapy Expert Joins Pacific Meso Center Research Team
Date:6/8/2012

LOS ANGELES, June 8, 2012 /PRNewswire/ -- The Pacific Meso Center (PMC) announces the appointment of its new scientific researcher for its laboratory on Santa Monica Boulevard. A graduate of the University of Southern California, Dr. Raymond M. Wong, Ph.D. joins the center after 5 years with MannKind Corporation, where he worked in cancer immunotherapy and specifically on preclinical development for MannKind's MKC-1106-MT and MKC-1106-PP cancer vaccine programs.

At PMC, Dr. Wong, who has a Ph.D. in immunology and whose work has been published in many scientific journals, will be responsible for planning and conducting the research on malignant pleural mesothelioma, an asbestos-related cancer affecting the pleura - the lining of the chest cavity. Dr. Robert B. Cameron, M.D., scientific advisor at PMC, stated, "Dr. Wong comes highly recommended and is an outstanding scientist with the research knowledge in immunology and immunotherapy who will help PMC develop promising immunotherapy treatments for mesothelioma patients at a time when immunotherapy has again become a focus of research for many cancers. He will be collaborating with Dr. Dongmei Hou of the Punch Worthington Research Laboratory at UCLA and with Dr. Saroj Basak of the Veterans Administration Medical Center in West Los Angeles." 

Dr. Wong also will collaborate with PMC's Scientific Advisor, Dr. Robert B. Cameron, who is a board certified cardiothoracic surgeon and surgical oncologist, the director of the UCLA Comprehensive Mesothelioma Program at the David Geffen School of Medicine at UCLA, Chief of Thoracic Surgery at the West Los Angeles Veterans Administration Medical Center, and a long-time proponent of lung-sparing surgery for malignant pleural mesothelioma. Together Drs. Wong and Cameron will work to advance therapeutic cancer immunotherapy strategies from pre-clinical stages to phase I/II clinical trials.

About Pacific Meso Center

The Pacific Meso Center (PMC), a division of The Pacific Heart, Lung & Blood Institute, was established in 2002 with the goal of becoming the most innovative research and treatment organization in the world for patients with malignant pleural mesothelioma (MPM), a rare form of cancer related to asbestos exposure. PMC focuses on specific areas of research that improve mesothelioma victims' lives and longevity, particularly those promising treatments that approach MPM as a chronic, treatable disease. The ultimate goal of PMC is finding a cure for mesothelioma.

For further information, please contact:

Clare Cameron
The Pacific Meso Center
310-478-4678
ccameron@phlbi.org
http://www.pacificmesocenter.org          

 

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

 


'/>"/>
SOURCE The Pacific Meso Center
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
3. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
4. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
5. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
6. Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS
7. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
10. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
11. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... San Diego-based ... of its corporate rebranding initiative announced today. The bold new look is part ... as the company moves into a significant growth period. , It will also expand ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the ... won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to ... Experience from US2020. , US2020’s mission is to change the trajectory of STEM ...
(Date:10/10/2017)... research firm Parks Associates announced today that Tom Kerber ... Annual Meeting , October 11 in Scottsdale, Arizona . ... how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... business process optimization firm for the life sciences and healthcare industries, announces a ... in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):